Improve quality and expand! The National Health Insurance Administration issued a new collection document “There is a lot of information” to set the tone for new trends in collection and procurement
① Yesterday evening, the National Health Insurance Administration issued the “Notice on Strengthening Regional Collaboration to Improve Quality and Expand Centralized Pharmaceutical Procurement in 2024", which provides further instructions on “improving quality and expansion” of collection; ② Many interprovincial alliance procurement will soon be upgraded to national joint procurement, which has attracted strong attention from the industry. In particular, the provinces covered by the Sanming Alliance and Henan Alternative Medicine Alliance will be further expanded, and proprietary Chinese medicine and Chinese medicine tablet companies need to prepare early.
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Hutchmed (China) Chairman Resigns, Successor Named
Hutchmed (China) (HKG:0013) said its chairman of the board of directors, Simon To, stepped down and will be succeeded by Dan Eldar, according to a Friday filing on the Hong Kong bourse. Price (HKD): $
Hong Kong stock bullish stocks this week | Vanke Enterprise rose nearly 40%, Sunac China rose more than 30%; Bilibili recorded four consecutive gains
Excellent performance boosted the stock price. Tencent Music accumulated a cumulative increase of nearly 19% during the week, and many institutions raised their target prices.
HUTCHMED's Breakthroughs in Hematology Spotlighted
Express News | Hehuang Pharmaceutical: Du Zhiqiang retires as chairman and executive director and will serve as the company's strategic advisor
Hutchmed (China) Chairman Simon To Resign; Dan Eldar Appointed Chairman
By Chris Wack Hutchmed (China) said Friday that Simon To has resigned as chairman and executive director and that Dan Eldar has been named as the company's new chairman effective immediately. The co
HUTCHMED Appoints New Chairman Amid Board Changes
Hehuang Pharmaceutical (00013) appoints Elder as new chairman
Hehuang Pharmaceutical (00013) issued an announcement. (a) Du Zhiqiang retired as chairman and executive director of the company after 23 years...
HUTCHMED to Present Promising Study Results at EHA2024
Hehuang Pharmaceutical (00013.HK): Will announce data on the 2024 European Hematology Association (EHA) ESLIM-01 phase III study and hematological malignancy project data
Gelonghui, May 17丨Hewang Pharmaceutical (00013.HK) announced today that it will announce the top line and subgroup results of the solepinib ESLIM-01 phase III study, as well as the latest and updated clinical data on innovative exploratory hematologic malignancy therapies HMPL-306, HMPL-760, and tazostat (tazostemetat) at the European Hematology Association (“EHA”) annual meeting to be held in Madrid and online from June 13 to June 16, 2024.
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to Be Presented at the Upcoming EHA2024 Congress
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association ("EHA") Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and online.
Hehuang Pharmaceutical (00013.HK): ESLIM-01 study results released, long-lasting response rate is impressive
Core view: Incident: Chi-Med released phase III clinical data (ESLIM-01) of solepinib for primary thrombocytopenia (ITP) at the 2024 EHA conference. According to the one issued by Hewang Pharmaceuticals
Analysts' Opinions Are Mixed on These Healthcare Stocks: HUTCHMED (HCM) and PAVmed (PAVM)
Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer
Hutchmed (HCM) said Tuesday it started a phase 2/3 trial of its drug candidate surufatinib in combination with nab-paclitaxel, gemcitabine and Jiangsu Hengrui's camrelizumab as a first-line treatment
Reported Earlier, HUTCHMED Initiates The RAPHAEL Registrational Phase III Trial Of HMPL-306 For Patients With IDH1- And/Or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia In China
HMPL-306 is a novel dual-inhibitor of IDH1 and IDH2 enzymes. Mutations of IDH1 and IDH2 have been implicated as drivers of certain hematological malignancies, gliomas and solid tumors, particularly am
Reported Earlier, HUTCHMED Initiates Phase II/III Trial Of The Combination Of Surufatinib And Camrelizumab For Treatment-Naïve Pancreatic Ductal Adenocarcinoma In Collaboration With Hengrui
Almost half a million people diagnosed each year across the globe —Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED's surufatinib
HUTCHMED Tests New Therapy for Pancreatic Cancer
Hutchmed Starts Phase 2/3 Trials for Pancreatic Cancer Drug in China; Shares Rise 3%
Hutchmed (HKG:0013) started its phase 2/3 trial for the combination of surufatinib and camrelizumab in patients with metastatic pancreatic ductal adenocarcinoma in China, according to a Tuesday filing
Hutchmed Begins Phase 3 Trials for Leukemia Medication in China
Hutchmed (HKG:0013) began its phase 3 trials for the HMPL-306 drug in patients with mutated isocitrate dehydrogenase 1 or 2 relapsed or refractory acute myeloid leukemia in China, according to a Tuesd
No Data